According to Innoviva's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 2.89151. At the end of 2023 the company had a P/S ratio of 2.87.
Year | P/S ratio | Change |
---|---|---|
2023 | 2.87 | 2.89% |
2022 | 2.79 | -8.78% |
2021 | 3.06 | -17.99% |
2020 | 3.73 | -32.12% |
2019 | 5.49 | -18.71% |
2018 | 6.76 | 1.54% |
2017 | 6.66 | -23.37% |
2016 | 8.69 | -61.26% |
2015 | 22.4 | -87.22% |
2014 | 175 | -79% |
2013 | 836 | 4632.16% |
2012 | 17.7 | -79.28% |
2011 | 85.2 | 2.48% |
2010 | 83.2 | 141.46% |
2009 | 34.4 | 22.12% |
2008 | 28.2 | -47.9% |
2007 | 54.1 | -42.93% |
2006 | 94.9 | 14.16% |
2005 | 83.1 |
Company | P/S ratio | P/S ratio differencediff. | Country |
---|---|---|---|
![]() OPKO Health
OPK | 1.44 | -50.11% | ๐บ๐ธ USA |
![]() Onconova Therapeutics ONTX | 72.4 | 2,403.58% | ๐บ๐ธ USA |